We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register to chat with like-minded investors on our interactive forums.
The current ORPOF market cap is 226.92M. The company's latest EPS is EUR -1.1759 and P/E is -6.68.
| Year End 31 December 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| EUR (€) | EUR (€) | EUR (€) | EUR (€) | EUR (€) | |
| Total Revenue | 25.95M | 10.43M | 26.31M | 18.3M | 2.23M |
| Operating Income | -1.47M | -18.99M | -16.6M | -18.4M | -22.99M |
| Net Income | -4.65M | -16.56M | -16.85M | -17.76M | -23M |
| Year End 31 December 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| EUR (€) | EUR (€) | EUR (€) | EUR (€) | EUR (€) | |
| Total Assets | 88.93M | 96.97M | 101.88M | 91.78M | 82.05M |
| Total Liabilities | 30.4M | 35.61M | 53.99M | 59.12M | 59.08M |
| Total Equity | 58.54M | 61.36M | 47.89M | 32.66M | 22.98M |
| Year End 31 December 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| EUR (€) | EUR (€) | EUR (€) | EUR (€) | EUR (€) | |
| Operating | 9.14M | -19.28M | -9.92M | -18.25M | -19.76M |
| Investing | 2.38M | -504k | -827k | 26k | -507k |
| Financing | 4.76M | 23.31M | 14.96M | 10.27M | 13.32M |
| Market Cap | 226.92M |
| Price to Earnings Ratio | -6.68 |
| Price to Sales Ratio | 68.98 |
| Price to Cash Ratio | 8.22 |
| Price to Book Ratio | 6.68 |
| Dividend Yield | - |
| Shares Outstanding | 19.56M |
| Average Volume (1 week) | 0 |
| Average Volume (1 Month) | 0 |
| 52 Week Change | - |
| 52 Week High | - |
| 52 Week Low | - |
| Spread (Intraday) | 0 (0%) |
| Company Name | OSE Immunotherapeutics SA (GM) |
| Address |
22 boulevard de benoni goullin nantes, loire-atlantique 44200 |
| Website | https://www.ose-immuno.com |
| Industry | coml physical, biologcl resh (8731) |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
